Simplifying Global Compliance
Items Tagged with 'Pricing'
Despite Abbott Laboratories' recent decision to cut the price of one of its HIV drugs in Thailand, an activist group is questioning the drugmaker's "quid pro quo" approach of lowering drug prices in exchange for halting compulsory licensing. Read More
The Centers for Medicare & Medicaid Services (CMS) rejected Wisconsin’s request to continue its prescription drug plan for seniors, which allowed the state to offer prescription drugs at lower prices through negotiations with drugmakers, Gov. Jim Doyle said. Read More
As advocates of bipartisan legislation aimed at lowering Medicare drug prices through direct government negotiation stepped up their efforts to garner support, some in the pharmaceutical industry believe such a policy shift would limit access to certain drugs under the government program. Read More
The UK National Health Service’s (NHS) drug price regulation scheme should be changed to a value-based system that focuses more on patients and improving benefits, according to an Office of Fair Trading (OFT) report. Read More
Two companies announced they are taking steps to provide easier access to needed medications in developing countries, while an advocacy group claimed a third company is preventing access to AIDS medication through an overload of patents. Read More
Government healthcare programs must require more price transparency and better reporting to stop pharmaceutical companies from overcharging them for medications, according to experts and activists testifying at a House committee hearing last week. Read More
Wyeth announced an increase of 17 percent in fourth quarter earnings, after sales of five pharmaceutical products reached more than $1 billion each in 2006. Read More
Bristol-Myers Squibb (BMS) reported a net loss from continuing operations of $134 million on sales of $4.2 billion in the fourth quarter of 2006, compared with net earnings of $499 million on sales of $5 billion for the same period in 2005. Read More
A new industry-backed study of Canada’s pharmaceutical reimbursement policy and listing recommendations made by four other countries concludes that Canadian patients have “significantly fewer” options when it comes to breakthrough medicines. Read More
Primary care trusts in the UK are being urged to recommend generic versions of statins to keep the high cost associated with the drugs under control, data in a new report shows. Read More
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing